摘要:
The present invention provides a method for the preparation of a human binding molecule, fragment or derivative thereof which specifically binds to the human CD3 complex. Furthermore, the invention provides a human binding molecules specifically binding to the human CD3 complex and means comprising said human binding molecules.
摘要:
The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged, from N-terminus to C-terminus, in the order VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3) or VH(CD3)-VL-(CD3)-VH(CD19)-VL (CD19). Processes for the production of the pharmaceutical compositions and medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are also disclosed.
摘要:
The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged, from N-terminus to C-terminus, in the order, VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3), VH(CD3)-VL-(CD3)-VH(CD19)-VL(CD19) or VH(CD3)-VL(CD3)-VL(CD19)-VH(CD19). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are disclosed.
摘要翻译:本发明涉及包含双特异性单链抗体构建体的药物组合物,所述双特异性单链抗体构建体包含对人CD3和人CD19特异的结合结构域,其中相应的可变重链区(V H H H) )和相应的可变轻链区域(V L L)区域从N末端到C末端按顺序排列,V H(CD19)-V (CD19)-V H(CD 3)-V L(CD 3),V H(CD 3) - (CD3)-V H(CD19)-VLL(CD19)或V H(H) (CD 3)-V L(CD 3)-V L(CD 19)-V H(CD 19)。 此外,公开了用于生产所述药物组合物的方法以及对于人CD3抗原和人CD19抗原具有特异性的特异性双特异性单链抗体分子的医学/药物用途。